Skip to main content
Premium Trial:

Request an Annual Quote

Pathway Genomics to Offer Tests Through Salud Interactiva

NEW YORK (GenomeWeb) – Pathway Genomics has signed an agreement to make its next-generation sequencing-based clinical genetic tests available in Mexico through health services provider Salud Interactiva, the companies announced today.

Specific terms of the deal were not disclosed.

Pathway sells a variety of NGS assays including ones for diet and weight loss, circulating tumor DNA mutations, hereditary cancer, and carrier screening, as well as metabolic response for commonly prescribed medications.

"Our research determined that the wide range of tests that Pathway offers are at the forefront of the genetic revolution we are seeing in healthcare today that is driving the trend towards predictive medicine," Salud Interactiva CMO and COO Eduardo Càrdenas said in a statement. "Physicians and users within our network will now have affordable access to information about how their own genetic blueprint impacts their health."

About a year ago, Pathway announced that it had partnered with G-TAC and Sony subsidiary M3 to market a number of its tests in Japan.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.